ELDN · XBRL financial data

Eledon Pharmaceuticals financial statements, every quarter

The same tables from 16 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ELDN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	7,931	7,067*	7,410	10,106	16,520	17,928*	13,531	20,276	14,969	17,491*	17,197	18,230
General and administrative	3,267	3,271*	3,459	4,396	3,990	6,768*	4,433	4,457	4,101	3,993*	3,984	4,639
Total operating expenses	11,198	10,338*	10,869	14,502	20,510	24,696*	17,964	24,733	19,070	21,484*	21,181	22,869
Operating income (loss)	(11,198)	(10,338)*	(10,869)	(14,502)	(20,510)	—	(17,964)	(24,733)	(19,070)	—	(21,181)	(22,869)
Other income (expense)	849	712*	574	869	1,042	1,439*	1,409	1,224	1,047	540*	1,118	862
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(10,349)	(85,837)*	(23,631)	(44,907)	76,971	(44,617)*	(6,495)	(11,216)	(17,459)	(10,447)*	(39,025)	(31,630)
Earnings per share, basic USD per share	(0.35)	—	(0.79)	(1.06)	1.05	—	(0.08)	(0.13)	(0.21)	(0.11)*	(0.33)	(0.27)
Earnings per share, diluted USD per share	(0.35)	—	(0.79)	(1.06)	(0.32)	—	(0.08)	(0.13)	(0.21)	(0.11)*	(0.33)	(0.27)
Weighted average shares, basic thousands of shares	29,974	29,979*	29,989	42,278	51,946	—	77,127	77,156	77,156	95,753*	112,424	113,632
Weighted average shares, diluted thousands of shares	29,974	29,979*	29,989	42,278	55,478	—	77,127	77,156	77,156	95,753*	112,424	113,632

Balance sheet

CSV

Fiscal quarters (ELDN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	3,667	4,612	5,655	26,039	6,751	20,549	8,496	5,741	3,669	22,808	6,152	6,803
Short-term investments	55,942	46,490	37,207	57,571	71,440	119,629	116,385	101,829	89,732	110,528	104,937	81,953
Prepaid and other current assets	3,382	5,027	5,115	3,611	3,318	3,552	2,837	3,834	2,900	2,352	2,485	4,335
Total current assets	62,991	56,129	47,977	87,221	81,509	143,730	127,718	111,404	96,301	135,688	113,574	93,091
Right-of-use asset	459	365	270	621	471	926	850	773	694	613	530	445
Goodwill	—	0	—	—	—	—	—	—	—	—	—	—
Total assets	96,069	89,066	80,818	120,483	114,576	177,405	161,308	144,909	129,857	169,009	146,667	126,094
Accounts payable	465	967	1,864	2,148	5,860	5,833	2,901	5,831	4,627	3,627	6,585	3,214
Total current liabilities	2,899	3,895	4,247	6,025	12,489	11,577	9,185	13,719	14,296	18,344	13,458	11,789
Lease liability, non-current	83	0	0	386	315	640	555	467	376	283	186	86
Total liabilities	4,734	81,858	95,546	128,984	38,518	59,265	46,728	38,881	38,803	32,230	46,209	54,063
Accumulated deficit	(233,565)	(319,402)	(343,033)	(387,940)	(310,969)	(355,586)	(362,081)	(373,297)	(390,756)	(401,203)	(440,228)	(471,858)
Total stockholders' equity	91,335	7,208	(14,728)	(8,501)	76,058	62,446	58,886	50,334	35,360	81,085	44,764	33,013
Total liabilities and equity	96,069	89,066	80,818	120,483	114,576	177,405	161,308	144,909	129,857	169,009	146,667	126,094
Common shares outstanding (cover page) thousands of shares	24,198	24,813	38,507	39,656	59,739	59,882	59,882	59,882	59,932	75,852	77,188	81,261

Cash flows

CSV

Fiscal quarters (ELDN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(10,349)	(85,837)*	(23,631)	(44,907)	76,971	(44,617)*	(6,495)	(11,216)	(17,459)	(10,447)*	(39,025)	(31,630)
Net cash from operating activities	(12,251)*	(9,131)*	(8,741)	(7,774)*	(11,769)*	(18,987)*	(16,060)	(17,713)*	(14,477)*	(14,091)*	(22,612)	(22,677)*
Net cash from investing activities	(25,029)*	10,076*	9,783	(19,913)*	(12,802)*	(47,382)*	3,892	14,958*	12,405*	(20,462)*	5,956	23,237*
Net cash from financing activities	0*	0*	1	48,071*	5,283*	80,167*	115	0*	0*	53,692*	—	—
Net change in cash	(37,280)*	945*	1,043	20,384*	(19,288)*	13,798*	(12,053)	(2,755)*	(2,072)*	19,139*	(16,656)	651*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Eledon Pharmaceuticals	6,803	not reported	(22,677)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	35,769	3,165	(25,842)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19,167	1,629	(19,847)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Vistagen Therapeutics	16,991	not reported	(14,707)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.